LBX(SH:603883) KAIYUAN SECURITIES·2025-08-28 13:52Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term pressure on operating performance but is expected to show a long-term stable growth trend, hence the "Buy" rating is maintained [5] - For the first half of 2025, the company achieved revenue of 10.774 billion yuan (down 1.51% year-on-year) and a net profit attributable to shareholders of 398 million yuan (down 20.86% year-on-year) [5] - The company has adjusted its profit forecasts for 2025-2026 and added a forecast for 2027, expecting net profits of 714 million yuan, 806 million yuan, and 918 million yuan for 2025, 2026, and 2027 respectively [5] Financial Performance Summary - In H1 2025, the company's gross margin was 33.08% (down 1.24 percentage points), and the net profit margin was 4.42% (down 0.96 percentage points) [5] - The sales expense ratio for H1 2025 was 21.88% (up 0.07 percentage points), while the management expense ratio was 4.62% (down 0.29 percentage points) [5] - The company’s revenue from pharmaceutical retail in H1 2025 was 8.815 billion yuan (down 2.30%), with a gross margin of 37.34% (down 1.07 percentage points) [6] Store Expansion and Market Strategy - As of H1 2025, the company operated a total of 15,385 stores, with 9,784 being direct-operated and 5,601 being franchised [7] - The company added 504 new stores during the reporting period, with 87% of the new stores located in lower-tier cities, indicating strong momentum in market expansion [7] Financial Projections - The company’s projected revenues for 2025, 2026, and 2027 are 22.76 billion yuan, 23.63 billion yuan, and 24.92 billion yuan respectively, with year-on-year growth rates of 1.8%, 3.8%, and 5.4% [8] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.94 yuan, 1.06 yuan, and 1.21 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 19.3, 17.2, and 15.0 [8]